Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Interleukin-31 may play a role in the pathobiologic mechanism of atopic dermatitis and pruritus. We wanted to assess the efficacy and safety of nemolizumab (CIM331), a humanized antibody against interleukin-31 receptor A, in the treatment of atopic dermatitis. METHODS: In this phase 2, randomized, double-blind, placebo-controlled, 12-week trial, we assigned adults with moderate-to-severe atopic dermatitis that was inadequately controlled by topical treatments to receive subcutaneous nemolizumab (at a dose of 0.1 mg, 0.5 mg, or 2.0 mg per kilogram of body weight) or placebo every 4 weeks or an exploratory dose of 2.0 mg of nemolizumab per kilogram every 8 weeks. The primary end point was the percentage improvement from baseline in the score on the pruritus visual-analogue scale (on which a negative change indicates improvement) at week 12. Secondary end points included changes in the score on the Eczema Area and Severity Index (EASI, on which a negative change indicates improvement), and body-surface area of atopic dermatitis. RESULTS: Of 264 patients who underwent randomization, 216 (82%) completed the study. At week 12, among the patients who received nemolizumab every 4 weeks, changes on the pruritus visual-analogue scale were -43.7% in the 0.1-mg group, -59.8% in the 0.5-mg group, and -63.1% in the 2.0-mg group, versus -20.9% in the placebo group (P<0.01 for all comparisons). Changes on the EASI were -23.0%, -42.3%, and -40.9%, respectively, in the nemolizumab groups, versus -26.6% in the placebo group. Respective changes in body-surface area affected by atopic dermatitis were -7.5%, -20.0%, and -19.4% with nemolizumab, versus -15.7% with placebo. Among the patients receiving nemolizumab every 4 weeks, treatment discontinuations occurred in 9 of 53 patients (17%) in the 0.1-mg group, in 9 of 54 (17%) in the 0.5-mg group, and in 7 of 52 (13%) in the 2.0-mg group, versus in 9 of 53 (17%) in the placebo group. CONCLUSIONS: In this phase 2 trial, nemolizumab at all monthly doses significantly improved pruritus in patients with moderate-to-severe atopic dermatitis, which showed the efficacy of targeting interleukin-31 receptor A. The limited size and length of the trial preclude conclusions regarding adverse events. (Funded by Chugai Pharmaceutical; XCIMA ClinicalTrials.gov number, NCT01986933 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a phase IIa study, the anti-IL-31Rα antibody nemolizumab led to a significant decrease in the pruritus sensation”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [189]
In the citing paper
“but the overall clinical inflammation as evaluated by the body surface area (BSA), EASI and IGA scorings did not improve significantly at this time point189.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [189]
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586 · cited 1×
“Japan 16 (30) 16 (30) 16 (30) 16 (31) 15 (29)”
Severity Scoring of Atopic Dermatitis: The SCORAD Index
(2009) · Dermatology · doi:10.1159/000247298 · Cited by 2,273
Bieber, T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra074081 · Cited by 1,780
Guidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,224 · cited 3×
“Not related to atopic dermatitis 1 (2) 1 (2) 0 1 (2) 1 (2)”
Self-citationThe eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.100102.x · Cited by 1,200
Self-citationIL-31: A new link between T cells and pruritus in atopic skin inflammation
Sonkoly, E., Muller, A., Lauerma, A. I., Pivarcsi, A., Soto, H., Kemeny, L., Alenius, H., Dieu-Nosjean, M.-C., Meller, S., Rieker, J., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.10.033 · Cited by 1,005
Self-citationGittler, J. K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K. J., Wang, C. Q. F., Mitsui, H., Cardinale, I., de Guzman Strong, C., Krueger, J. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.012 · Cited by 981 · cited 1×
“4 22 (42) 18 (34) 25 (46) 25 (48) 22 (42)”
Guidelines of care for the management of atopic dermatitis
Sidbury, R., Davis, D. M., Cohen, D. E., Cordoro, K. M., Berger, T. G., Bergman, J. N., Chamlin, S. L., Cooper, K. D., Feldman, S. R., Hanifin, J. M., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.030 · Cited by 885 · cited 1×
“(%)† 8 (15) 9 (17) 6 (11) 5 (10) 7 (13)”
Self-citationCevikbas, F., Wang, X., Akiyama, T., Kempkes, C., Savinko, T., Antal, A., Kukova, G., Buhl, T., Ikoma, A., Buddenkotte, J., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.10.048 · Cited by 804 · cited 2×
“(%)† 7 (13) 11 (21) 10 (19) 11 (21) 9 (17)”
Guidelines for treatment of atopic eczema (atopic dermatitis) Part I
Ring, J., Alomar, A., Bieber, T., Deleuran, M., Fink‐Wagner, A., Gelmetti, C., Gieler, U., Lipozencic, J., Luger, T., Oranje, A. P., et al. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04635.x · Cited by 683
Self-citation
Research works printed but not linked: 2
- Oyama S, Exp Dermatol
- Lichstein KL, 2006, Sleep, 29, 232
Cited by
Items 401–500 of 588
First eczema biologic debuts but price could restrict use
Dolgin, E. (2017) · Nature Biotechnology · doi:10.1038/nbt0517-391 · Cited by 5
Hereditary angioneurotic edema … a disease has been described
Bellanti, J. A., & Settipane, R. A. (2017) · Allergy and Asthma Proceedings · doi:10.2500/aap.2017.38.4102 · Cited by 5
Antisense molecules: A promising new therapy for atopic dermatitis
Xue, J., & Yao, Z. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.09.008 · Cited by 5
“Nemolizumab, which targets IL-31 receptor α , has demonstrated promising efficacy in alleviating itching and improving symptoms in AD patients aged 12 years and older 16 , but the efficacy of this biologic was only temporary, suggesting that IL-31 has no upstream role in the pathogenesis of AD 147 .”
Nemolizumab for the treatment of atopic dermatitis
Rodrigues, E., Domingues, J., Alvarenga, J. M., Chovatiya, R., & Torres, T. R. (2025) · Journal of Dermatological Treatment · doi:10.1080/09546634.2025.2576134 · Cited by 4
Zhang, H., Xiang, W., Tong, Y., Jiang, X., & Guo, L. (2025) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-025-09115-5 · Cited by 4
Wan, L., Zhou, Z., Chen, Q., Jing, J., & Xu, G. (2026) · Inflammation Research · doi:10.1007/s00011-026-02186-w · Cited by 4
High Serum IL-31 Concentration Is Associated with Itch among Renal Transplant Recipients
Krajewski, P. K., Tyczyńska, K. M., Bardowska, K., Olczyk, P., Nowicka‐Suszko, D., Janczak, D., Augustyniak‐Bartosik, H., Krajewska, M., & Szepietowski, J. C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154309 · Cited by 4
Establishment of an experimental model of ovalbumin-induced atopic dermatitis in canines
Shin, H.-Y., Jin, H. J., Tae, H., Oh, H.-G., & Hwang, J. H. (2024) · Frontiers in Veterinary Science · doi:10.3389/fvets.2024.1296138 · Cited by 4
Antibody-Based Biotherapeutics in Inflammatory Diseases
Xu, Y. C., Chen, J., & Zhou, H. (2024) · Springer eBooks · doi:10.1007/978-3-031-30023-3_24 · Cited by 5
CytoSIP: an annotated structural atlas for interactions involving cytokines or cytokine receptors
Wang, L., Sun, F., Li, Q., Ma, H., Zhong, J., Zhang, H., Cheng, S., Wu, H., Zhao, Y., Wang, N., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06289-0 · Cited by 5
Advances of the exposome at individual levels and prevention in atopic dermatitis
Xian, M., Maskey, A., Kopulos, D., & Li, X.-M. (2024) · International Journal of Dermatology · doi:10.1111/ijd.17559 · Cited by 5
A new era for translational atopic dermatitis research and management
Kabashima, K., & Biedermann, T. (2018) · Experimental Dermatology · doi:10.1111/exd.13546 · Cited by 4
Self-citationManagement of severe atopic dermatitis in adult patients
Kobusiewicz, A. K., Zalewska-Janowska, A. M., Lesiak, A., & Narbutt, J. (2020) · Dermatology Review · doi:10.5114/dr.2020.97785 · Cited by 4
Nowicki, R. J., Trzeciak, M., Rudnicka, L., Szepietowski, J. C., Kulus, M., Kupczyk, M., Mastalerz–Migas, A., Peregud-Pogorzelski, J. W., Jahnz‐Różyk, K., Narbutt, J., et al. (2020) · Advances in Dermatology and Allergology · doi:10.5114/ada.2020.100496 · Cited by 6
A conversation on allergy: recognizing the past and looking to the future
Melén, E., Lambrecht, B. N., Lloyd, C. M., Rothenberg, M. E., Kabashima, K., Luciani, F., Coquet, J. M., Ober, C., Nawijn, M. C., Platts‐Mills, T. A. E., et al. (2023) · Immunology and Cell Biology · doi:10.1111/imcb.12688 · Cited by 4
“6,72,73 In line with the efficacy of several new biologics, we have come to a greater appreciation of endotypes of allergy, which greatly inform patient treatment options.”
BackgroundSelf-citationSkin Barrier Dysfunction in Contact Dermatitis and Atopic Dermatitis-Treatment Implications
Aviv, H., Herzinger, T., & Molin, S. (2020) · Current Treatment Options in Allergy · doi:10.1007/s40521-020-00264-w · Cited by 5
Ogura, M., Endo, K., Suzuki, T., & Homma, Y. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246630 · Cited by 4
“Nemolizumab, an IL-31R-neutralizing humanized antibody, is effective in improving pruritus in AD patients, but clinical studies have shown that exacerbation of dermatitis and peripheral edema are observed in some patients [43,44].”
BackgroundBrown, S. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15646 · Cited by 4
Schweres atopisches Ekzem oder primärer Immundefekt?
Wollenberg, A., Renner, E. D., & Hagl, B. (2017) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-017-0330-y · Cited by 4
Self-citationStanescu, L.-S., Ghemigian, A. M., Ciobica, M.-L., Nistor, C., Ciuche, A., Radu, A.-M., Şandru, F., & Carşote, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25189765 · Cited by 3
Mucherino, S., Raimondo, A., Krstin, M., Aznar‐Lou, I., Serino, M., Perrella, L., Bernardi, F. F., Trama, U., Menditto, E., Lembo, S., et al. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17101279 · Cited by 3
Ellis, J., Fortunato, L., Wajdner, H., DUCA, E. D., Barnard, J., Betts, J. C., Bose, S. N., Browning, J., Buil‐Bruna, N., Buren, S. V., et al. (2025) · Allergy · doi:10.1111/all.70172 · Cited by 6
Zdanowska, N., Machoń, N. J., Frączek, A., Kasprowicz‐Furmańczyk, M., Czerwińśka, J., & Owczarczyk-Saczonek, A. B. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1849265 · Cited by 3
Ibrutinib response in cutaneous transformed lymphoplasmacytic lymphoma
Lindholm, K. E., Forsberg, P. A., & Ewalt, M. D. (2021) · eJHaem · doi:10.1002/jha2.253 · Cited by 3
Lee, G. R., Lee, D. E., & Shi, V. Y. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-84744-5.00023-1 · Cited by 3
Pereira, M. P., Nau, T., Zeidler, C., & Ständer, S. (2018) · Der Hautarzt · doi:10.1007/s00105-018-4145-2 · Cited by 3
Serra‐Baldrich, E., Santamaria‐Babí, L. F., & Silvestre, J. F. (2022) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2022.06.001 · Cited by 3
Revisiting immunotherapeutic strategies for the management of atopic dermatitis
Siwe, G. T., Fajemisin, E. A., Mugeri, M., Naran, K., & Barth, S. (2024) · doi:10.37349/eaa.2024.00052 · Cited by 4
Nouveaux traitements et perspectives thérapeutiques dans la dermatite atopique
Huet, F., Gouin, O., & Misery, L. (2020) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2020.01.020 · Cited by 3
Biologics for Allergic Dermatologic Diseases
Bilimoria, S. N., & Lio, P. (2020) · Current Allergy and Asthma Reports · doi:10.1007/s11882-020-00923-7 · Cited by 3
Scratching Beyond the Surface of Itchy Wounds
Yang, T.-L. B., & Kim, B. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.016 · Cited by 3
Takamura, S., & Teraki, Y. (2021) · The Journal of Dermatology · doi:10.1111/1346-8138.15937 · Cited by 3
Ferrara, F., Zovi, A., Capuozzo, M., García-Montero, J., Zavaleta‐Monestel, E., & Langella, R. (2024) · Current Dermatology Reports · doi:10.1007/s13671-024-00423-1 · Cited by 5
L’actuel et le futur du traitement de la dermatite atopique de l’adulte
Lacour, J. ‐. (2017) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/s0151-9638(18)30089-9 · Cited by 3
Neurokinin‐1 and cytokine receptors as targets for therapy of chronic prurigo
Wallengren, J. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16031 · Cited by 4
Les traitements systémiques de la dermatite atopique
Lacour, J. ‐. (2019) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/s0151-9638(20)30017-x · Cited by 3
Pruritus: From the Bench to the Bedside
Reich, A., Misery, L., & Takamori, K. (2018) · BioMed Research International · doi:10.1155/2018/5742753 · Cited by 3
Pregabalin as a Potential Adjunct in the Management of Pruritus in Prurigo Nodularis: A Case Report
Mima, Y., Yamamoto, M., & Iozumi, K. (2025) · Cureus · doi:10.7759/cureus.88297 · Cited by 2
Methods to Validate Digital Health Technologies for Dermatology
Park, J. J.-Y., Richards, D., Tseng, P.-H., Ebata, T., Ikoma, A., Vakharia, P. P., Rangel, S. M., Paller, A. S., & Xu, S. (2025) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2025.08.013 · Cited by 2
Understanding cutaneous sensory syndromes: diagnostic challenges and treatment implications
Patel, J. D., & Jafferany, M. (2026) · Clinical and Experimental Dermatology · doi:10.1093/ced/llag107 · Cited by 2
Latest Breakthroughs in the Treatment of Atopic Dermatitis
Skayem, C., & Duong, T. A. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.104344 · Cited by 2
More from the Pipeline of Clinical Research on SELECTED SYSTEMIC THERAPIES FOR ATOPIC DERMATITIS.
Rosso, J. Q. D. (2019) · Europe PMC (PubMed Central) · Cited by 4
Homey, B., Ruzicka, T., & Wollenberg, A. (2018) · Springer eBooks · doi:10.1007/978-3-662-49544-5_32 · Cited by 3
Self-citationHomey, B., Ruzicka, T., & Wollenberg, A. (2022) · Springer eBooks · doi:10.1007/978-3-662-63709-8_32 · Cited by 2
Self-citationNeuartige Therapien auf der Grundlage der Pathophysiologie der atopischen Dermatitis
Bieber, T. R. M. (2019) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13965_g · Cited by 2
Lehman, H. K., & Sabella, C. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-95061-9.00039-4 · Cited by 2
Atopic Dermatitis, The Skin‐Disease
Wallach, D. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14487 · Cited by 2
Nakahara, T., & Furue, M. (2018) · Current Treatment Options in Allergy · doi:10.1007/s40521-018-0191-3 · Cited by 2
Self-citationSnir, V. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-72156-9_19 · Cited by 2
Orteu, C. H., & Denton, C. P. (2024) · Wiley eBooks · doi:10.1002/9781119709268.rook054 · Cited by 2
Masukane, S., & Taketani, T. (2025) · Cureus · doi:10.7759/cureus.83810 · Cited by 4
“Nemolizumab has been demonstrated to rapidly reduce pruritus in AD by blocking IL-31RA and disrupting pruriceptive signaling [5,10].”
24-week real world outcomes of nemolizumab in patients with prurigo nodularis
Mima, Y., Yamamoto, M., & Iozumi, K. (2026) · Journal of Dermatological Treatment · doi:10.1080/09546634.2026.2624225 · Cited by 1
Tashjian, M., Rankin, E., Tehrani, L., Ruppe, M., & Riskin, S. I. (2026) · Cureus · doi:10.7759/cureus.107961 · Cited by 1
Skin Lipid Dysregulation in Atopic Dermatitis and Related Inflammatory Skin Diseases
Kim, H. B., Park, J. S., Lim, C. S., Um, J., Chung, B. Y., Park, C. W., Lee, D., & Kim, H. O. (2026) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2026.18.4.485 · Cited by 1
Biologika-Therapie der atopischen Dermatitis
Quint, T., & Bangert, C. (2020) · hautnah · doi:10.1007/s12326-020-00418-2 · Cited by 1
Nakamura, T., & Yamamoto, T. (2024) · International Journal of Dermatology · doi:10.1111/ijd.17374 · Cited by 1
Sugiyama, A., Nakahara, T., Kojima, K., Nishie, H., Nishimura, M., & Hiramoto, T. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14248657 · Cited by 1
Combination therapy with dupilumab and nemolizumab for refractory itch in atopic dermatitis
Nguyen, W., Bahar, K., & Yamauchi, P. S. (2026) · JAAD Case Reports · doi:10.1016/j.jdcr.2026.01.010 · Cited by 1
Decision-Making Factors for Systemic Therapies in Atopic Dermatitis: A Clinical Review
Levine, J. P., Mehta, A., O’Hagan, R., Guttman-Yassky, E., & Lamb, A. J. (2026) · Dermatitis · doi:10.1177/17103568261423754 · Cited by 2
Alopecia Areata and Atopic Dermatitis: Common Mechanisms and Emerging Therapeutics
Tang, A., Rachko, G., Margiotta, F. M., Levine, J. P., DUCA, E. D., & Ungar, B. (2026) · Journal of Inflammation Research · doi:10.2147/jir.s549496 · Cited by 2
Fernández, P. L., Butler, B., Theis, H., Paulusch, S., Domenico, E. D., Weir, G. A., & Bell, A. M. (2026) · Pain · doi:10.1097/j.pain.0000000000004102 · Cited by 1
“By measuring cell size with emerging imaging-enabled cell sorters[48], it may soon be possible to selectively enrich LTMR-versus nociceptor-sized neurons directly from flash-frozen post-mortem tissue.”
Deng, K., Huang, J., Wu, Q., Xie, J., Yang, X., Yang, S., Liu, L., 龚亚方, Shen, W., Cai, L., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1821901 · Cited by 1
“Moreover, systemic administration is associated with significantly higher risks of systemic AEs compared to topical delivery (Simpson et al., 2016; Ruzicka et al., 2017).”
Banović, F., Austel, M. G., Johnson, L., & von Simson, C. (2026) · Veterinary Dermatology · doi:10.1111/vde.70102 · Cited by 1
Li, L., Yu, J., Huang, D., Zhou, H., Mo, N., Hu, W., & Qian, F. (2026) · Archives of Dermatological Research · doi:10.1007/s00403-026-04692-7 · Cited by 1
Kaliciak, I., & Korda, O. (2026) · Cureus · doi:10.7759/cureus.112165 · Cited by 1
“Neuroimmune signaling provides a biological explanation for the strong link between itch and sleep fragmentation [1-3, 23,24].”
Antibody-Based Biotherapeutics in Inflammatory Diseases
Zhou, H., Xu, Y. C., & Sharma, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-00710-2_26 · Cited by 2
[ATOPIC DERMATITIS: ADVANCES IN UNDERSTANDING OF ITCH AND EFFICACY OF MOLECULAR TARGETED AGENTS].
Murota, H. (2019) · PubMed · doi:10.15036/arerugi.68.815 · Cited by 1
A new era in the treatment of atopic dermatitis
Lebwohl, M. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18349 · Cited by 1
Kursewicz, C. D., Fourzali, K. M., & Yosipovitch, G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-84744-5.00025-5 · Cited by 1
Sung, M., Koh, Y., Kim, M., Kim, H., Na, J., Nahm, D., Min, T. K., Park, Y., Lee, D. H., Lee, M.-H., et al. (2024) · Allergy Asthma & Respiratory Disease · doi:10.4168/aard.2024.12.2.58 · Cited by 1
Wenyu, W., Yu, F., Tao, X., Yang, X., Xiaoling, X., & Chen, B. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1503312 · Cited by 1
Biologics for the Treatment of Atopic Dermatitis
Hajar, T., Hill, E., & Simpson, E. L. (2017) · Springer eBooks · doi:10.1007/978-3-319-66884-0_31 · Cited by 1
Investigations on the expression and relevance of nerve growth factor in dogs with atopic dermatitis
Olivry, T., & Bizikova, P. (2019) · Itch · doi:10.1097/itx.0000000000000022 · Cited by 2
Pharmacodynamic Evaluation: Dermatology
Bik, L., & Thio, H. B. (2018) · Springer eBooks · doi:10.1007/978-3-319-56637-5_36-1 · Cited by 2
Additional Biologic Therapeutics
Grinich, E. E., & Simpson, E. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-61211-1.00031-0 · Cited by 1
Nowicki, R. J., Trzeciak, M., Rudnicka, L., Szepietowski, J. C., Kulus, M., Kupczyk, M., Mastalerz–Migas, A., Peregud-Pogorzelski, J. W., Jahnz‐Różyk, K., Narbutt, J., et al. (2020) · Alergologia Polska - Polish Journal of Allergology · doi:10.5114/pja.2020.102084 · Cited by 2
Médecine personnalisée dans la dermatite atopique
Lefevre, M.-A., Braun, C., Vocanson, M., & Nosbaum, A. (2020) · Revue française d'allergologie · doi:10.1016/s1877-0320(20)30481-4 · Cited by 1
Nowicki, R. J., Trzeciak, M., Rudnicka, L., Szepietowski, J. C., Kulus, M., Kupczyk, M., Mastalerz–Migas, A., Peregud-Pogorzelski, J. W., Jahnz‐Różyk, K., Narbutt, J., et al. (2020) · Dermatology Review · doi:10.5114/dr.2020.101669 · Cited by 1
Le prurit : de la physiopathologie à la thérapeutique
Misery, L. (2021) · Douleur et Analgésie · doi:10.3166/dea-2021-0160 · Cited by 1
Case report of the dupilumab applying in atopic dermatitis child
Revyakina, V. A., Анатольевна, Л. И., Kuvshinova, E. D., Мухортых, В. А., & Melnikova, K. S. (2021) · Russian Journal of Allergy · doi:10.36691/rja1424 · Cited by 1
Advances in Therapy for Atopic Dermatitis
Zhou, N. Y., Bilimoria, S. N., & Lio, P. (2022) · Journal of the Dermatology Nurses’ Association · doi:10.1097/jdn.0000000000000658 · Cited by 1
Pharmacodynamic Evaluation: Dermatology
Bik, L., & Thio, H. B. (2020) · Springer eBooks · doi:10.1007/978-3-319-68864-0_36 · Cited by 1
Serra‐García, L., & Morgado‐Carrasco, D. (2020) · Piel · doi:10.1016/j.piel.2019.10.016 · Cited by 1
Villa, A. L. V., Fraga, A. G. M., dos Santos, E. P., & Siqueira, B. N. (2022) · Infarma - Ciências Farmacêuticas · doi:10.14450/2318-9312.v34.e2.a2022.pp181-192 · Cited by 1
Revisit on the Use of Bleach Baths as a Standardized Treatment for Atopic Dermatitis
Chan, J. Y. (2022) · Pediatric Respirology and Critical Care Medicine · doi:10.4103/prcm.prcm_19_21 · Cited by 1
Atopik Dermatit Güncel Patofizyolojisi
Çalıcıoğlu, F., Avcı, A., Ertaş, R., & Ulaş, Y. (2024) · Journal of Anatolian Medical Research · doi:10.55694/jamer.1403931 · Cited by 1
I Disordini Atopici Primari: come riconoscerli e come intervenire
Calzoni, E., Castagnoli, R., Giardino, G., Corrente, S., Leonardi, L., Cinicola, B. L., Federici, S., Volpi, S., Torre, F. L., Soresina, A., et al. (2022) · Rivista di immunologia ed allergologia pediatrica. · doi:10.53151/2531-3916/2022-8 · Cited by 1
L’actualité scientifique vue par les étudiants de l’AMPS
Benani, A., Gaudet, C., Varennes, O., & Vellas, D. (2018) · médecine/sciences · doi:10.1051/medsci/20183404011 · Cited by 1
Reszke, R., & Szepietowski, J. C. (2019) · Wiley eBooks · doi:10.1002/9781119476009.ch13 · Cited by 1
Current Drug Treatments for Allergy
Layhadi, J. A., Palmer, E., Sharif, H., & Shamji, M. H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00236-5 · Cited by 1
Dermatologic Pharmacotherapeutics
Jeromin, A. M. (2019) · Wiley eBooks · doi:10.1002/9781119404576.ch18 · Cited by 1
Potential applications of three-dimensional bioprinting in regenerative medicine
Kwan, D. C. M. (2017) · Cambridge Medicine Journal · doi:10.7244/cmj.2017.03.002
Systemic Therapy of Atopic Dermatitis: When, How, for How Long?
Malik, K., & Guttman‐Yassky, E. (2017) · Current Dermatology Reports · doi:10.1007/s13671-017-0176-7
Schweres atopisches Ekzem: IL-31-Rezeptor-Antikörper nimmt den Juckreiz
Kreutzkamp, B. (2017) · Allergo Journal · doi:10.1007/s15007-017-1363-3
Perspektiven der Therapie von Pigmentierungs- und Barrierestörungen
Klein, F. (2017) · hautnah dermatologie · doi:10.1007/s15012-017-2524-5
Treatment of atopic dermatitis with cyclosporin A: a case report
Kaaz, K., & Reich, A. (2017) · Dermatology Review · doi:10.5114/dr.2017.69950 · Cited by 1
Morgado‐Carrasco, D., Fustà‐Novell, X., Riera‐Monroig, J., & Iranzo, P. (2017) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2017.08.011
Quoi de neuf en thérapeutique dermatologique ?
Viguier, M. A. (2017) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/s0151-9638(17)31065-7
Neuer Therapieansatz beim schweren atopischen Ekzem
Mutschler, U. (2017) · Pädiatrie · doi:10.1007/s15014-017-1149-9
American Academy of Dermatology Annual Meeting: San Diego, CA, USA, 16–20 Feb 2018
Fraser, K. A. (2018) · American Journal of Clinical Dermatology · doi:10.1007/s40257-018-0351-z
Metadata
- Authors
- Ruzicka, T., Hanifin, J. M., Furue, M., Pulka, G., Mlynarczyk, I., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Yoshida, H., Stewart, J., & Kabashima, K.
- Affiliations
- Jagiellonian University (PL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-03-02
- Volume
- 376
- Issue
- 9
- Pages
- 826-835
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2593200577
- Cited by
- 592
- References
- 40
- Citations by year
- 2026: 30 · 2025: 34 · 2024: 49 · 2023: 41 · 2022: 45 · 2021: 87 · 2020: 73 · 2019: 95 · 2018: 82 · 2017: 52
- FWCI
- 94.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Chugai Pharmaceutical
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- atopic dermatitis, nemolizumab, pruritus, Eczema Area and Severity Index, body surface area involvement, treatment efficacy and safety, dose comparison, treatment discontinuation, adverse events, moderate-to-severe atopic dermatitis, adults, biologic therapy
- MeSH terms
- Adult, Dermatitis, Atopic, Edema, Female, Humans, Male, Middle Aged, Pruritus, Receptors, Interleukin, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.